Receive our newsletter – data, insights and analysis delivered to you

Can open-source research prevent a Covid resurgence?

By Paul Dennis

4 March

Dean Baker, senior economist at the Centre for Economic and Policy Research (CEPR), shared an article on preventing the resurgence of the pandemic with open-source research.

In his opinion, even though the current pandemic seemed to be nearing its end, public health officials have been cautioning about new virus strains, which the current vaccines are not designed to fight.

The issue of protecting intellectual property claims in the pandemic has also been gaining significant attention, with India and South Africa putting forward a resolution to suspend patent and other intellectual property claims on vaccines, tests, and treatments, during the coronavirus pandemic.

However, the US and other rich countries stand to oppose it.

Economists believe it is time for drug manufacturers such as Pfizer and Moderna, who have specific knowledge of the manufacturing processes involved, to directly share their expertise.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Baker also highlights the problem of transparency in the results shared by vaccine makers.

He opines that it would be ideal if all the companies fully disclosed their clinical trial results so that the world could benefit from them.

Read more

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy